Applications of QSAR Methods to Ion Channels

Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals

Volumn , Issue , 2006, Pages 353-389

  Aronov, Alex M ^a   Balakin, Konstantin V ^b   Kiselyov, Alex ^b   Varma O'Brien, Shikha ^c   Ekins, Sean ^d  

^a VERTEX PHARMACEUTICALS   (United States)

^b CHEMDIV INC   (United States)

^c ACCELRYS INC   (United States)

^d ACT LLC   (United States)

Author keywords

Calcium channel blockers (CCB) and L type calcium channels (LCCs); Potassium channels; QSAR method application in ion channels

Indexed keywords

EID: 84255193086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470145890.ch13     Document Type: Chapter

References (148)

1. Terlau H, Stuhmer W. Structure and function of voltage-gated ion channels. Naturwissenschaften 1998;85:437-44.
2. Triggle DJ, Gopalakrishnan M, Rampe D, Zheng W, editors. Voltage-gated ion channels as drug targets. Weinheim: Wiley-VCHV, 2006.
3. Catterall WA, Chandy KG, Gutman GA, editors. The IUPHAR compendium of voltage-gated ion channels. Leeds: IUPHAR Media, 2002.
4. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. An Intern Med 1995; 122:701-14.
5. Thomas SH. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13:77-102.
6. Barry DM, Xu H, Schuessler RB, Nerbonne JM. Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 alpha subunit. Circ Res 1998;83:560-7.
7. Jeron A, Mitchell GF, Zhou J, Murata M, London B, Buckett P, et al. Inducible polymorphic ventricular tachyarrhythmias in a transgenic mouse model with a long Q-T phenotype. Am J Physiol Heart Circ Physiol 2000;278:H1891-8.
8. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-5.
9. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-42.
10. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
11. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;286:788-93.
12. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120:968-74.
13. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, et al. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Meth 2004;50:187-99.
14. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? Areview of emerging trends.J Pharmacol Toxicol Meth 2006;53:87-105.
15. Rajamani R, Tounge BA, Li J, Reynolds CH. A two-state homology model of the hERG K(+) channel: application to ligand binding. Bioorg Med Chem Lett 2005;15:1737-41.
16. Zhou Y, Morais-Cabral JH, Kaufman A, MacKinnon R. Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 Å resolution. Nature 2001;414:43-8.
17. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002;417:515-22.
18. Jiang Y, Lee A, Chen J, Ruta V, Cadene M, Chait BT, et al. X-ray structure of a voltage-dependent K+ channel. Nature 2003;423:33-41.
19. Cavalli A, Poluzzi E, De Ponti F, Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem 2002;45:3844-53.
20. Morgan TK, Jr., Sullivan ME. An overview of class III electrophysiological agents: A new generation of antiarrhythmic therapy. Prog Med Chem 1992;29:65-108.
21. Matyus P, Borosy AP, Varro A, Papp JG, Barlocco D, Cignarella G. Development of pharmacophores for inhibitors of the rapid component of the cardiac delayed rectifier potassium current. Int J Quant Chem 1998;69:21-30.
22. SYBYL. St. Louis, MO: Tripos Inc., 1997.
23. Liu H, Ji M, Jiang H, Liu L, Hua W, Chen K, et al. Computer-aided design, synthesis and biological assay of p-methylsulfonamido phenylethylamine analogues. Bioorg Med Chem Lett 2000;10:2153-7.
24. Liu H, Ji M, Luo X, Shen J, Huang X, Hua W, et al. New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: Design, synthesis, biological assay, and 3D-QSAR analysis. J Med Chem 2002;45:2953-69.
25. Tong W, Lowis DR, Perkins R, Chen Y, Welsh WJ, Goddette DW, et al. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 1998;38:669-77.
26. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002;301:427-34.
27. Catalyst. San Diego, CA: Accelrys, 2001.
28. Crumb Jr WJ, Ekins S, Sarazan D, Wikel JH, Wrighton SA, Carlson C, et al. Effects of antipsychotic drugs on Ito, INa, Isus, IK1, and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 2006;23:1133-43.
29. Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem Soc Trans 2003;31:611-4.
30. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003;13:1829-35.
31. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today 2004;9:276-85.
32. Ekins S, Balakin KV, Savchuk N, Ivanenkov Y. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning, Kohonen and Sammon mapping techniques. J Med Chem 2006;49:5059-71.
33. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, et al. MacroModel-An integrated software system for modeling organic and bio-organic molecules using molecular mechanics. J Comput Chem 1990;1:440-67.
34. Chang G, Guida WC, Still WC. An internal coordinate Monte Carlo method for searching conformational space. J Am Chem Soc 1989;111:4379-86.
35. Keseru GM. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett 2003;13:2773-5.
36. Du LP, Tsai KC, Li MY, You QD, Xia L. The pharmacophore hypotheses of I(Kr) potassium channel blockers: Novel class III antiarrhythmic agents. Bioorg Med Chem Lett 2004;14:4771-7.
37. Aptula AO, Cronin MT. Prediction of hERG K+ blocking potency: Application of structural knowledge. SAR QSAR Environ Res 2004;15:399-411.
38. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
39. Buyck C. An in silico model for detecting potential HERG blocking. In: Ford M, Livingstone D, Dearden J, Van de Waterbeemd H, editors, EuroQSAR 2002 Designing drugs and crop protectants: Processes, problems, and solutions. Oxford: Blackwell Publishing, 2003. p. 86-9.
40. Song M, Clark M. Development and evaluation of an in silico model for HERG binding. J Chem Inf Model 2006;46:392-400.
41. Clark M. Generalized fragment-substructure based property prediction method. J Chem Inf Model 2005;45:30-8.
42. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the HERG channel drug binding site. J Biol Chem 2004;279:10120-7. Epub 2003 Dec 29.
43. Yoshida K, Niwa T. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J Chem Inf Model 2006;46:1371-8.
44. Fletcher SR, Burkamp F, Blurton P, Cheng SK, Clarkson R, O'Connor D, et al. 4-(Phenylsulfonyl)piperidines: Novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem 2002;45:492-503.
45. Rowley M, Hallett DJ, Goodacre S, Moyes C, Crawforth J, Sparey TJ, et al. 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem 2001;44:1603-14.
46. Bell IM, Gallicchio SN, Abrams M, Beese LS, Beshore DC, Bhimnathwala H, et al. 3-Aminopyrrolidinone farnesyltransferase inhibitors: Design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. J Med Chem 2002;45:2388-409.
47. Ekins S, Swaan PW. Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX. Rev Comp Chem 2004;20:333-415.
48. Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. ChemBioChem 2002;3:455-9.
49. Ghose AK, Crippen GM. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships: I. Partition coefficients as a measure of hydrophobicity. J Comput Chem 1986;7:565-77.
50. TSAR. Oxford, UK: Oxford Molecular Ltd.
51. Schneider G, Neidhart W, Giller T, Schmid G. "Scaffold-hopping" by topological pharmacophore search: A contribution to virtual screening. Angew Chem Int Ed Engl 1999;38:2894-6.
52. VolSurf. Perugia, Italy: Multivariate Infometric Analysis S.r.l.
53. DRAGON. Milano, Italy: Milano Chemometrics and QSAR group.
54. Sun H. An accurate and interpretable Bayesian classification model for prediction of hERG liability. ChemMedChem 2006;1:315-22.
55. Aronov AM, Goldman BB. A model for identifying HERG K+ channel blockers. Bioorg Med Chem 2004;12:2307-15.
56. Carhart RE, Smith DH, Venkataraghavan R. Atom pairs as molecular features in structure-activity studies: Definition and application. J Chem Inf Comput Sci 1985;25:64-73.
57. Mitcheson JS, Perry MD. Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Devel 2003;6:667-74.
58. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, et al. Structural determinants of HERG channel block by clofilium and ibu-tilide. Mol Pharmacol 2004;66:240-9.
59. Testai L, Bianucci AM, Massarelli I, Breschi MC, Martinotti E, Calderone V. Torsadogenic cardiotoxicity of antipsychotic drugs: A structural feature, potentially involved in the interaction with cardiac HERG potassium channels. Curr Med Chem 2004;11:2691-706.
60. Wang N, DeLisle RK, Diller DJ. Fast small molecule similarity searching with multiple alignment profiles of molecules represented in one-dimension. J Med Chem 2005;48:6980-90.
61. Vapnik V. Statistical learning theory. New York: Wiley, 1998.
62. Tobita M, Nishikawa T, Nagashima R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg Med Chem Lett 2005;15:2886-90.
63. Molecular Operating Environment (MOE). Montreal, Canada: Chemical Computing Group Inc., 2002.
64. Bains W, Basman A, White C. HERG binding specificity and binding site structure: Evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol 2004;86:205-33.
65. Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel: A model for bad behavior. J Med Chem 2003;46:2017-22.
66. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-33.
67. Balakin KV, Ivanenkov YA, Savchuk NP, Ivaschenko AA, Ekins S. Comprehensive computational assessment of ADME properties using mapping techniques. Curr Drug Disc Tech 2005;2:99-113.
68. Du LP, Li MY, Tsai KC, You QD, Xia L. Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochem Biophys Res Commun 2005;332:677-87.
69. DOCK5. San Francisco: University of California, San Francisco.
70. Carosati E, Lemoine H, Spogli R, Grittner D, Mannhold R, Tabarrini O, et al. Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothi-azine type K(ATP)-channel openers. Bioorg Med Chem 2005;13:5581-91.
71. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S. GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional Molecular descriptors. J Med Chem 2000;43:3233-43.
72. Uhrig U, Holtje HD, Mannhold R, Weber H, Lemoine H. Molecular modeling and QSAR studies on K(ATP) channel openers of the benzopyran type. J Mol Graph Model 2002;21:37-45.
73. Peukert S, Brendel J, Pirard B, Bruggemann A, Below P, Kleemann HW, et al. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5. J Med Chem 2003;46:486-98.
74. Peukert S, Brendel J, Pirard B, Strubing C, Kleemann HW, Bohme T, et al. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett 2004;14:2823-7.
75. Favre I, Moczydlowski E, Schild L. On the structural basis for ionic selectivity among Na+, K+, and Ca2+ in the voltage-gated sodium channel. Biophys J 1996;71:3110-25.
76. Anger T, Madge DJ, Mulla M, Riddall D. Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem 2001;44:115-37.
77. Li Y, Harte WE. A review of molecular modeling approaches to pharmacophore models and structure-activity relationships of ion channel modulators in CNS. Curr Pharm Des 2002;8:99-110.
78. Khodorov BI. Sodium inactivation and drug-induced immobilization of the gating charge in nerve membrane. Prog Biophys Mol Biol 1981;37:49-89.
79. Rein KS, Baden DG, Gawley RE. Conformational analysis of the sodium channel modulator, Brevetoxin A, comparison with brevetoxin B conformations, and a hypothesis about the common pharmacophore of the "site 5" toxins. J Org Chem 1994;59:2101-6.
80. Unverferth K, Engel J, Hofgen N, Rostock A, Gunther R, Lankau HJ, et al. Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles. J Med Chem 1998;41:63-73.
81. Kuo CC, Huang RC, Lou BS. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: Molecular determinants of selective binding to the inactivated channels. Mol Pharmacol 2000;57:135-43.
82. Tasso SM, Moon S, Bruno-Blanch LE, Estiu GL. Characterization of the anticonvulsant profile of valpromide derivatives. Bioorg Med Chem 2004;12:3857-69.
83. Malawska B, Kulig K, Spiewak A, Stables JP. Investigation into new anticonvulsant derivatives of alpha-substituted N-benzylamides of gamma-hydroxy-and gamma-acetoxybutyric acid: Part 5. Search for new anticonvulsant compounds. Bioorg Med Chem 2004;12:625-32.
84. De Luca A, Talon S, De Bellis M, Desaphy JF, Lentini G, Corbo F, et al. Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol Pharmacol 2003;64:932-45.
85. Pandeya SN, Raja AS, Stables JP. Synthesis of isatin semicarbazones as novel anticonvulsants-Role of hydrogen bonding. J Pharm Pharm Sci 2002;5:266-71.
86. Hays SJ, Rice MJ, Ortwine DF, Johnson G, Schwarz RD, Boyd DK, et al. Substituted 2-benzothiazolamines as sodium flux inhibitors: Quantitative structure-activity relationships and anticonvulsant activity. J Pharm Sci 1994;83:1425-32.
87. Brown ML, Brown GB, Brouillette WJ. Effects of log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel. J Med Chem 1997;40:602-7.
88. Brown ML, Zha CC, Van Dyke CC, Brown GB, Brouillette WJ. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem 1999;42:1537-45.
89. Zha C, Brown GB, Brouillette WJ. Synthesis and structure-activity relationship studies for hydantoins and analogues as voltage-gated sodium channel ligands. J Med Chem 2004;47:6519-28.
90. Huang CJ, Harootunian A, Maher MP, Quan C, Raj CD, McCormack K, et al. Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol 2006;24:439-46.
91. Ekins S, Johnston JS, Bahadduri P, D'Souzza VM, Ray A, Chang C, et al. In vitro and pharmacophore based discovery of novel hPEPT1 inhibitors. Pharm Res 2005;22:512-7.
92. Lipkind GM, Fozzard HA. KcsA crystal structure as framework for a molecular model of the Na+ channel pore. Biochemistry 2000;39:8161-70.
93. Scheib H, McLay I, Guex N, Clare JJ, Blaney FE, Dale TJ, et al. Modeling the pore structure of voltage-gated sodium channelsin closed, open, fast-inactivated conformation reveals details of site 1 toxin and local anaesthetic binding. J Mol Model 2005;12:813-22.
94. McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Disc Today 2006;11:245-53.
95. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev 2004;23:223-38.
96. Kubota K, Pearce GL, Inman WH. Vasodilation-related adverse events in diltia-zem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol 1995;48:1-7.
97. Cantrell FL, Clark RF, Manoguerra AS. Determining triage guidelines for unintentional overdoses with calcium channel antagonists. Clin Toxicol (Phila) 2005;43:849-53.
98. Cantrell FL, Williams SR. Fatal unintentional overdose of diltiazem with ante-mortem and postmortem values. Clin Toxicol (Phila) 2005;43:587-8.
99. Doyle DA, Cabral JM, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, et al. The structure of the potassium channel: Molecular basis of K+ conduction and selectivity. Science 1998;280:69-77.
100. Zhorov BS, Folkman EV, Ananthanarayanan VS. Homology model of dihydropyridine receptor: implications for L-type Ca2+ channel modulation by agonists and antagonists. Arch Biochem Biophys 2001;393:22-41.
101. Zhorov BS, Ananthanarayanan VS. Docking of verapamil in a synthetic Ca2+ channel: Formation of a ternary complex involving Ca2+ ions. Arch Biochem Biophys 1997;341:238-44.
102. Lipkind GM, Fozzard HA. Molecular modeling of interactions of dihydropyri-dines and phenylalkylamines with the inner pore of the L-type Ca2+ channel. Mol Pharmacol 2003;63:499-511.
103. Triggle DJ. L-type calcium channels. Curr Pharm Des 2006;12:443-57.
104. Catterall WA. Structure and function of voltage-sensitive ion channels. Science 1988;242:50-61.
105. Varadi G, Strobeck M, Koch S, Caglioti L, Zucchi C, Palyi G. Molecular elements of ion permeation and selectivity within calcium channels. Crit Rev Biochem Mol Biol 1999;34:181-214.
106. Randall A, Benham CD. Recent advances in the molecular understanding of voltage-gated Ca2+ channels. Mol Cell Neurosci 1999;14:255-72.
107. Striessing J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H. Structural bases of drug binding to L-Ca2+ channels. Trends Pharm Sci 1998;19:108-15.
108. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. An Rev Cell Dev Biol 2000;16:521-55.
109. Hu H, Marban E. Isoform-specific inhibition of L-type calcium channels by dihy-dropyridines is independent of isoform-specific gating properties. Mol Pharmacol 1998;53:902-7.
110. Striessing J. Pharmacology, structure and function of cardiac L-type calcium channels. Cell Physiol Biochem 1999;9:242-69.
111. Mahmoudian M, Richards WG. QSAR of binding of dihydropyridine-type calcium antagonists to their receptor on ileal smooth muscle preparations. J Pharm Pharmacol 1986;38:272-6.
112. Goll A, Glossmann H, Mannhold R. Correlation between the negative inotropic potency and binding parameters of 1,4-dihydropyridine and phenylalkylamine calcium channel blockers in cat heart. Naunyn Schmiedebergs Arch Pharmacol 1986;334:303-12.
113. Fujimura K, Ota A, Kawashima Y. Quantitative structure-activity relationships of Ca(2+)-antagonistic semotiadil congeners. Chem Pharm Bull (Tokyo) 1996; 44:542-6.
114. Baxter AJ, Dixon J, Ince F, Manners CN, Teague SJ. Discovery and synthesis of methyl 2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: The first examples of a new class of calcium channel activator. J Med Chem 1993;36:2739-44.
115. Mager PP, Coburn RA, Solo AJ, Triggle DJ, Rothe H. QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: A difficult road ahead. Drug Des Discov 1992;8:273-89.
116. Hemmateenejad B, Akhond M, Miri R, Shamsipur M. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. In: Application of the Hansch analysis method. Weinheim: Arch Pharm, 2002. p. 472-80.
117. Hasegawa K, Miyashita Y, Funatsu K. GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists. J Chem Inf Comput Sci 1997;37:306-10.
118. Hemmateenejad B, Akhond M, Miri R, Shamsipur M. Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyri-dines (nifedipine analogs). J Chem Inf Comput Sci 2003;43:1328-34.
119. Hemmateenejad B, Safarpour MA, Miri R, Taghavi F. Application of ab initio theory to QSAR study of 1,4-dihydropyridine-based calcium channel blockers using GA-MLR and PC-GA-ANN procedures. J Comput Chem 2004;25:1495-503.
120. Viswanadhan VN, Mueller GA, Basak SC, Weinstein JN. Comparison of a neural net-based QSAR algorithm (PCANN) with Hologram-and multiple linear regression-based QSAR approaches: application to 1,4-dihydropyridine-based calcium channel antagonists. J Chem Inf Comput Sci 2001;41:505-11.
121. Takahata Y, Costa MC, Gaudio AC. Comparison between neural networks (NN) and principal component analysis (PCA): Structure activity relationships of 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues). J Chem Inf Comput Sci 2003;43:540-4.
122. Si HZ, Wang T, Zhang KJ, Hu ZD, Fan BT. QSAR study of 1,4-dihydropyridine calcium channel antagonists based on gene expression programming. Bioorg Med Chem 2006;Mar 29: published on the Web.
123. Seidel W, Meyer H, Born L, Kazda K, Dompert W. Rigid calcium antagonists of the nifedipine type: Geometrical requirements for the dihydropyridine receptor. In: Seydel J, editor, QSAR and strategies in the design of bioactive compounds. Weinheim: VCH, 1985. p. 366-9.
124. Belvisi L, Brossa S, Salimbeni A, Scolastico C, Todeschini R. Structure-activity relationship of Ca2+ channel blockers: A study using conformational analysis and chemometric methods. J Comput Aided Mol Des 1991;5:571-84.
125. Ivanciuc O, Ivanciuc T, Cabrol-Bass D. Comparative receptor surface analysis (CoRSA) model for calcium channel antagonists. SAR QSAR Environ Res 2001;12:93-111.
126. Doddareddy MR, Jung HK, Cha JH, Cho YS, Koh HY, Chang MH, et al. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA. Bioorg Med Chem 2004;12:1613-21.
127. Kharkar PS, Desai B, Gaveria H, Varu B, Loriya R, Naliapara Y, et al. Threedimensional quantitative structure-activity relationship of 1,4-dihydropyridines as antitubercular agents. J Med Chem 2002;45:4858-67.
128. Corelli F, Manetti F, Tafi A, Campiani G, Nacci V, Botta M. Diltiazem-like calcium entry blockers: A hypothesis of the receptor-binding site based on a comparative molecular field analysis model. J Med Chem 1997;40:125-31.
129. Davis AM, Gensmantel NP, Johansson E, Marriott DP. The use of the GRID program in the 3-D QSAR analysis of a series of calcium-channel agonists. J Med Chem 1994;37:963-72.
130. Budriesi R, Carosati E, Chiarini A, Cosimelli B, Cruciani G, Ioan P, et al. A new class of selective myocardial calcium channel modulators: 2. Role of the acetal chain in oxadiazol-3-one derivatives. J Med Chem 2005;48:2445-56.
131. Schleifer K-J. Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state. J Med Chem 1999;42:2204-11.
132. Goldmann S, Stoltefuss J. 1,4-Dihydropyridines: influence of chirality and conformation to the calcium antagonistic and agonistic effect. Angew Chem 1991;103:1587-605.
133. Benigni R, Cotta-Ramusino M, Gallo G, Giorgi F, Giuliani A, Vari MR. Deriving a quantitative chirality measure from molecular similarity indices. J Med Chem 2000;43:3699-703.
134. Clark M, Cramer III RD, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem 1989;10:982-1012.
135. Gupta SP, Veerman A, Bagaria P. Quantitative structure-activity relationship studies on some series of calcium channel blockers. Mol Divers 2004;8:357-63.
136. Yao X, Liu H, Zhang R, Liu M, Hu Z, Panaye A, et al. QSAR and classification study of 1,4-dihydropyridine calcium channel antagonists based on least squares support vector machines. Mol Pharm 2005;2:348-56.
137. Filimonov D, Poroikov V, Borodina Y, Gloriozova T. Chemical similarity assessment through multilevel neighborhoods of atoms: Definition and comparison with the other descriptors. J Chem Inf Comput Sci 1999;39:666-70.
138. Poroikov VV, Filimonov DA, Borodina YV, Lagunin AA, Kos A. Robustness of biological activity spectra predicting by computer program PASS for nonconge-neric sets of chemical compounds. J Chem Inf Comput Sci 2000;40:1349-55.
139. Ivanenkov YA, Balakin KV, Savchuk NP, Nikolsky Y. Design of ion channel-targeted libraries using unsupervised machine learning approach. In: Intelligent drug discovery and development. Philadelphia, PA, 2003. p. 27-30.
140. Seidel JK. Drug-membrane interactions and pharmacodynamics. In Methods and Principles in medicinal Chemistry. In: Mannhold R, Kubinyi H, Folkers G, editors, Methods and priniciples in medicinal chemistry. Weinheim: Wiley-VCH, 2002. p. 217-89.
141. Barbato F, LaRotonda IM, Quaglia F. Chromatographic indexes on immobilized artificial membranes for local anaesthetics: relationships with activity data on closed sodium channels. Pharm Res 1997;14:1699-705.
142. Wikel JH, Bemis KG, Kurz K, Denney ML, Main BW, Moore RA, et al. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers. Drug Des Discov 1994;11:1-14.
143. Rojratanakiat W, C.H. The relative dependence of calcium antagonists and neuroleptics binding to brain and heart receptors on drug lipophilicity. J Pharm Pharmacol 1990;42:599-600.
144. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Meth 2000;44:251-72.
145. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Meth 2005;52:136-45.
146. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999;84:989-98.
147. Kang J, Chen XL, Wang H, Ji J, Reynolds W, Lim S, et al. Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 2004;308:935-40.
148. Delano WL. The PyMol user's manual. San Carlos, CA.: DeLano Scientific, 2002.